Global Regulators Face Up to "Biosimilar" Complexity

This article gives an up-to-date summary of the current EU situation on "follow-on biologics" and describes the draft guideline and concept papers issued by the EMEA in November/ December 2004. This article follows on from the Hogan & Hartson EU Bulletin published in the summer of 2004.


Download PDF Share Back To Listing
Loading data